Advertisement

Journal of Molecular Medicine

, Volume 86, Issue 1, pp 29–35 | Cite as

Thymosin β4 and Ac-SDKP: Tools to mend a broken heart

  • Alex Rossdeutsch
  • Nicola Smart
  • Paul R. RileyEmail author
Review

Abstract

Thymosin β4 – an endogenously occurring 43 amino acid peptide – has recently been shown to possess cardioprotective properties in the setting of acute myocardial infarction. This review focuses on the reported mechanisms of action through which Thymosin β4 might accomplish this effect and the clinical prospects for its use as a therapeutic agent.

Keywords

Thymosin β4 Acute myocardial infarction Cardioprotective properties 

References

  1. 1.
    Safer D, Golla R, Nachmias VT (1990) Isolation of a 5-kilodalton actin-sequestering peptide from human blood platelets. Proc Natl Acad Sci USA 87:2536–2540PubMedCrossRefGoogle Scholar
  2. 2.
    Safer D, Elzinga M, Nachmias VT (1991) Thymosin beta 4 and Fx, an actin-sequestering peptide, are indistinguishable. J Biol Chem 266:4029–4032PubMedGoogle Scholar
  3. 3.
    Huff T, Muller CS, Otto AM, Netzker R, Hannappel E (2001) beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 33:205–220PubMedCrossRefGoogle Scholar
  4. 4.
    Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D (2004) Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 432:466–472PubMedCrossRefGoogle Scholar
  5. 5.
    Tu Y, Li F, Goicoechea S, Wu C (1999) The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol 19:2425–2434PubMedGoogle Scholar
  6. 6.
    Fukuda T, Chen K, Shi X, Wu C (2003) PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J Biol Chem 278:51324–51333PubMedCrossRefGoogle Scholar
  7. 7.
    Brazil DP, Park J, Hemmings BA (2002) PKB binding proteins. Getting in on the Akt. Cell 111:293–303PubMedCrossRefGoogle Scholar
  8. 8.
    Woodgett JR (2005) Recent advances in the protein kinase B signaling pathway. Curr Opin Cell Biol 17:150–157PubMedCrossRefGoogle Scholar
  9. 9.
    Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S (2003) Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation. J Biol Chem 278:22374–22378PubMedCrossRefGoogle Scholar
  10. 10.
    Smart N, Risebro CA, Melville AA, Moses K, Schwartz RJ, Chien KR, Riley PR (2007) Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization. Nature 445:177–182PubMedCrossRefGoogle Scholar
  11. 11.
    Bhaskar PT, Hay N (2007) The two TORCs and akt. Dev Cell 12:487–502PubMedCrossRefGoogle Scholar
  12. 12.
    Sano M, Minamino T, Toko H, Miyauchi H, Orimo M, Qin Y, Akazawa H, Tateno K, Kayama Y, Harada M, Shimizu I, Asahara T, Hamada H, Tomita S. Molkentin JD, Zou Y, Komuro I (2007) p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446:444–448PubMedCrossRefGoogle Scholar
  13. 13.
    Shiojima I, Sato K, Izumiya Y, Schiekofer S, Ito M, Liao R, Colucci WS, Walsh K (2005) Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115:2108–2118PubMedCrossRefGoogle Scholar
  14. 14.
    Conlon JM, Grimelius L, Wallin G, Thim L (1988) Isolation and structural characterization of thymosin-beta 4 from a human medullary thyroid carcinoma. J Endocrinol 118:155–159PubMedCrossRefGoogle Scholar
  15. 15.
    Hall AK (1991) Differential expression of thymosin genes in human tumors and in the developing human kidney. Int J Cancer 48:672–677PubMedCrossRefGoogle Scholar
  16. 16.
    Yamamoto T, Gotoh M, Kitajima M, Hirohashi S (1993) Thymosin beta-4 expression is correlated with metastatic capacity of colorectal carcinomas. Biochem Biophys Res Commun 193:706–710PubMedCrossRefGoogle Scholar
  17. 17.
    Chen C, Li M, Yang H, Chai H, Fisher W, Yao Q (2005) Roles of thymosins in cancers and other organ systems. World J Surg 29:264–270PubMedCrossRefGoogle Scholar
  18. 18.
    Cha HJ, Jeong MJ, Kleinman HK (2003) Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst 95:1674–1680PubMedGoogle Scholar
  19. 19.
    Larsson LI, Holck S (2007) Occurrence of thymosin beta4 in human breast cancer cells and in other cell types of the tumor microenvironment. Hum Pathol 38:114–119PubMedCrossRefGoogle Scholar
  20. 20.
    Grant DS, Kinsella JL, Kibbey MC, LaFlamme S, Burbelo PD, Goldstein A L, Kleinman HK (1995) Matrigel induces thymosin beta 4 gene in differentiating endothelial cells. J Cell Sci 108(Pt 12):3685–3694PubMedGoogle Scholar
  21. 21.
    Malinda KM, Goldstein AL, Kleinman HK (1997) Thymosin beta 4 stimulates directional migration of human umbilical vein endothelial cells. FASEB J 11:474–481PubMedGoogle Scholar
  22. 22.
    Koutrafouri V, Leondiadis L, Avgoustakis K, Livaniou E, Czarnecki J, Ithakissios DS, Evangelatos GP (2001) Effect of thymosin peptides on the chick chorioallantoic membrane angiogenesis model. Biochim Biophys Acta 1568:60–66PubMedGoogle Scholar
  23. 23.
    Frangogiannis NG (2006) Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 13:1877–1893PubMedCrossRefGoogle Scholar
  24. 24.
    Tillmanns J, Carlsen H, Blomhoff R, Valen G, Calvillo L, Ertl G, Bauersachs J, Frantz S (2006) Caught in the act: in vivo molecular imaging of the transcription factor NF-kappaB after myocardial infarction. Biochem Biophys Res Commun 342:773–774PubMedCrossRefGoogle Scholar
  25. 25.
    Hall G, Hasday JD, Rogers TB (2006) Regulating the regulator: NF-kappaB signaling in heart. J Mol Cell Cardiol 41:580–591PubMedCrossRefGoogle Scholar
  26. 26.
    Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109:S81–S96 (Suppl)PubMedCrossRefGoogle Scholar
  27. 27.
    Sosne G, Qiu P, Christopherson PL, Wheater MK (2007) Thymosin beta 4 suppression of corneal NFkappaB: A potential anti-inflammatory pathway. Exp Eye Res 84:663–669PubMedCrossRefGoogle Scholar
  28. 28.
    Morishita R, Sugimoto T, Aoki M, Kida I, Tomita N, Moriguchi A, Maeda K, Sawa Y, Kaneda Y, Higaki J, Ogihara T (1997) In vivo transfection of cis element “decoy” against nuclear factor-kappaB binding site prevents myocardial infarction. Nat Med 3:894–899PubMedCrossRefGoogle Scholar
  29. 29.
    Cavasin MA, Rhaleb NE, Yang XP, Carretero OA (2004) Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP. Hypertension 43:1140–1145PubMedCrossRefGoogle Scholar
  30. 30.
    Wang D, Carretero OA, Yang XY, Rhaleb NE, Liu YH, Liao TD, Yang XP (2004) N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. Am J Physiol Heart Circ Physiol 287:H2099–H2105PubMedCrossRefGoogle Scholar
  31. 31.
    Liu JM, Lawrence F, Kovacevic M, Bignon J, Papadimitriou E, Lallemand JY, Katsoris P, Potier P, Fromes Y, Wdzieczak-Bakala J (2003) The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. Blood 101:3014–3020PubMedCrossRefGoogle Scholar
  32. 32.
    Waeckel L, Bignon J, Liu JM, Markovits D, Ebrahimian TG, Vilar J, Mees B, Blanc-Brude O, Barateau V, Le Ricousse-Roussanne S, Duriez M, Tobelem G, Wdzieczak-Bakala J, Levy BI, Silvestre JS (2006) Tetrapeptide AcSDKP induces postischemic neovascularization through monocyte chemoattractant protein-1 signaling. Arterioscler Thromb Vasc Biol 26:773–779PubMedCrossRefGoogle Scholar
  33. 33.
    Yang F, Yang XP, Liu YH, Xu J, Cingolani O, Rhaleb, NE., Carretero OA (2004) Ac-SDKP reversesss inflammation and fibrosis in rats with heart failure after myocardial infarction. Hypertension 43:229–236PubMedCrossRefGoogle Scholar
  34. 34.
    Huff T, Otto AM, Muller CS, Meier M, Hannappel E (2002) Thymosin beta4 is released from human blood platelets and attached by factor XIIIa (transglutaminase) to fibrin and collagen. FASEB J 16:691–696PubMedCrossRefGoogle Scholar
  35. 35.
    Mora CA, Baumann CA, Paino JE, Goldstein AL, Badamchian M (1997) Biodistribution of synthetic thymosin beta 4 in the serum, urine, and major organs of mice. Int J Immunopharmacol 19:1–8PubMedCrossRefGoogle Scholar
  36. 36.
    Naito AT, Tominaga A, Oyamada M, Oyamada Y, Shiraishi I, Monzen K, Komuro I, Takamatsu T (2003) Early stage-specific inhibitions of cardiomyocyte differentiation and expression of Csx/Nkx-2.5 and GATA-4 by phosphatidylinositol 3-kinase inhibitor LY294002. Exp Cell Res 291:56–69PubMedCrossRefGoogle Scholar
  37. 37.
    McDevitt TC, Laflamme MA, Murry CE (2005) Proliferation of cardiomyocytes derived from human embryonic stem cells is mediated via the IGF/PI 3-kinase/Akt signaling pathway. J Mol Cell Cardiol 39:865–873PubMedCrossRefGoogle Scholar
  38. 38.
    Condorelli G, Drusco A, Stassi G, Bellacosa A, Roncarati R, Iaccarino G, Russo MA, Gu Y, Dalton N, Chung C, Latronico MV, Napoli C, Sadoshima J, Croce CM, Ross J Jr (2002) Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci USA 99:12333–12338PubMedCrossRefGoogle Scholar
  39. 39.
    Matsui T, Li L, Wu JC, Cook SA, Nagoshi T, Picard MH, Liao R Rosenzweig A (2002) Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277:22896–22901PubMedCrossRefGoogle Scholar
  40. 40.
    Shiojima I, Walsh K (2006) Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 20:3347–3365PubMedCrossRefGoogle Scholar
  41. 41.
    Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K (2000) Akt promotes survival of cardiomyocytes in vitro and protects against ischemia–reperfusion injury in mouse heart. Circulation 101:660–667PubMedGoogle Scholar
  42. 42.
    Hausenloy DJ, Yellon DM (2006) Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 70:240–253PubMedCrossRefGoogle Scholar
  43. 43.
    Young JD, Lawrence AJ, MacLean AG, Leung BP, McInnes IB, Canas B, Pappin DJ, Stevenson RD (1999) Thymosin beta 4 sulfoxide is an anti-inflammatory agent generated by monocytes in the presence of glucocorticoids. Nat Med 5:1424–1427PubMedCrossRefGoogle Scholar
  44. 44.
    Sosne G, Szliter EA, Barrett R, Kernacki KA, Kleinman H, Hazlett LD (2002) Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury. Exp Eye Res 74:293–299PubMedCrossRefGoogle Scholar
  45. 45.
    Badamchian M, Fagarasan MO, Danner RL, Suffredini AF, Damavandy H, Goldstein AL (2003) Thymosin beta(4) reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int Immunopharmacol 3:1225–1233PubMedCrossRefGoogle Scholar
  46. 46.
    Leeanansaksiri W, DeSimone SK, Huff T, Hannappel E, Huff TF (2004) Thymosin beta 4 and its N-terminal tetrapeptide, AcSDKP, inhibit proliferation, and induce dysplastic, non-apoptotic nuclei and degranulation of mast cells. Chem Biodivers 1:1091–1100PubMedCrossRefGoogle Scholar
  47. 47.
    Wyczolkowska J, Walczak-Drzewiecka A, Wagner W, Dastych J (2007) Thymosin beta4 and thymosin beta4-derived peptides induce mast cell exocytosis. Peptides 28:752–759PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Alex Rossdeutsch
    • 1
  • Nicola Smart
    • 1
  • Paul R. Riley
    • 1
    Email author
  1. 1.UCL Institute of Child HealthLondonUK

Personalised recommendations